Marksans Pharma Secures UK MHRA Approval for Exemestane Breast Cancer Treatment
核心洞察
Marksans Pharma's UK subsidiary Relonchem (搜索) received marketing authorization from UK MHRA (搜索) for Exemestane 25mg film-coated tablets, a breast cancer treatment.
The regulatory approval drove Marksans Pharma shares up 1.26 percent to Rs 189.10 in opening trade on November 6.
This follows Relonchem (搜索)'s October approval for Clonidine tablets from UK MHRA (搜索), expanding the company's regulatory portfolio in the UK market.
Marksans Pharma's wholly owned UK subsidiary Relonchem (搜索) has secured marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Exemestane 25mg film-coated tablets, a treatment used in breast cancer therapy. The regulatory approval announcement drove the parent company's shares higher in early trading on November 6.
Market Response to Regulatory Milestone
Marksans Pharma shares rose 1.26 percent to Rs 189.10 at 09:20am on the BSE, gaining Rs 2.35 from the previous session's close of Rs 186.75. The positive market reaction reflects investor confidence in the company's expanding regulatory footprint in the UK pharmaceutical market.
The stock's performance comes after a challenging period, with shares currently trading 47.25 percent below their 52-week high of Rs 358.50 reached on December 5, 2024. However, the current price represents a 16.69 percent premium to the 52-week low of Rs 162.05 recorded on October 7, 2025.
Expanding UK Portfolio
The Exemestane approval represents the latest in a series of regulatory successes for Relonchem (搜索) in the UK market. In October, the subsidiary received marketing authorization for Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets from UK MHRA (搜索), demonstrating the company's systematic approach to building its UK product portfolio.
Corporate Updates
Marksans Pharma has scheduled a board meeting for November 13, 2025, to review and approve unaudited financial results for both standalone and consolidated operations for the quarter and half-year ended September 30, 2025. The company maintains a market capitalization of Rs 8,569.33 crore as of the current trading session.